Sanofi's lixisenatide diabetes drug shows positive results
http://www.knowabouthealth.com/sanofis-lixisenatide-diabetes-drug-shows-positive-results/6547/

sanofi 's lixisenatide diabetes drug shows positive results  pharmaceutical companies are aggressively looking into development of drugs for patients suffering from type-2 diabetes mellitus . we read about priamal , indian pharma company , entering into phase-ii trial with its p1736-05 compound . sanofi reported results of phase -- iii trial , getgoal clinical trial program . the program was designed to assess the efficacy and safety of lixisenatide , a once-daily glp-1 receptor agonist , as monotherapy in patients with type 2 diabetes .  about the studylixisenatide , a glucagon-like peptide-1 agonist ( glp-1 ) , is in development for the treatment of patients with type 2 diabetes mellitus . the study included :  population of 361 patients with type 2 diabetes .  randomly receipt of either lixisenatide , the sanofi 's diabetes injectable , or a placebo treatment .  is part of the new glp-1 class of diabetes drugs . other pharma giants are also working on this class of drugs , such as byetta , marketed by eli lilly &amp; co. and amylin pharmaceuticals inc , and novo nordisk glp-1 class drug like novo nordisk 's victoza was approved with a warning about the risk for thyroid cancer and the requirement of a risk-mitigation strategy .